Cite

    Kfoury, M. et al. (2022). Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer treatment reviews. p. . [Online].